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Purpose:  To  correlate  intra  voxel  incoherent  motion  (IVIM)  diffusion  parameters  of  liver parenchyma  and
hepatocellular  carcinoma  (HCC)  with  degree  of liver/tumor  enhancement  and  necrosis;  and  to  assess  the
diagnostic  performance  of  diffusion  parameters  vs. enhancement  ratios  (ER)  for  prediction  of  complete
tumor  necrosis.
Patients and methods:  In this  IRB  approved  HIPAA  compliant  study,  we  included  46  patients  with  HCC
who  underwent  IVIM  diffusion-weighted  (DW)  MRI  in  addition  to routine  sequences  at 3.0  T.  True  dif-
fusion  coefﬁcient  (D), pseudo-diffusion  coefﬁcient  (D*),  perfusion  fraction  (PF)  and  apparent  diffusion
coefﬁcient  (ADC)  were  quantiﬁed  in tumors  and  liver  parenchyma.  Tumor  ER were  calculated  using
contrast-enhanced  imaging,  and  degree  of  tumor  necrosis  was  assessed  using  post-contrast  image  sub-
traction. IVIM  parameters  and  ER  were  compared  between  HCC  and  background  liver and  between
necrotic  and  viable  tumor  components.  ROC  analysis  for  prediction  of  complete  tumor  necrosis  was
performed.
Results:  79 HCCs  were assessed  (mean  size  2.5 cm).  D, PF and  ADC  were  signiﬁcantly  higher  in HCC vs.
liver  (p  <  0.0001).  There  were  weak  signiﬁcant  negative/positive  correlations  between  D/PF  and  ER, and
signiﬁcant  correlations  between  D/PF/ADC  and  tumor  necrosis  (for  D,  r 0.452,  p  < 0.001).  Among  diffusion
parameters,  D had the  highest  area  under  the curve  (AUC  0.811)  for predicting  complete  tumor  necrosis.
ER  outperformed  diffusion  parameters  for prediction  of complete  tumor  necrosis  (AUC  > 0.95,  p  <  0.002).
Conclusion:  D has  a reasonable  diagnostic  performance  for predicting  complete  tumor  necrosis,  however
lower  than  that  of  contrast-enhanced  imaging.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. IntroductionRecently, diffusion-weighted MRI  (DW-MRI) has become more
outinely used in the liver, with applications including tumor
etection/characterization, evaluation of response to therapy, and
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ncoherent motion; PF, perfusion fraction (%).
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assessment of diffuse liver disease [1–3]. Most published studies on
DW-MRI have quantiﬁed the apparent diffusion coefﬁcient (ADC)
using a simple mono-exponential ﬁt of signal intensity vs. b value.
Pre-clinical studies in hepatocellular carcinoma (HCC) have shown
that tumor necrosis yield higher ADC values compared with viable
tumor components [4,5], with an observed increase in ADC after
locoregional or systemic therapy [6–8]. These results have been
veriﬁed in human HCC studies, which have suggested that ADC
increases after therapy [9–13], or correlates with necrotic changes
post therapy [14].
The diffusion signal intensity decay vs. b value may  follow a
non-monoexponential law, as there is an effect of microcirculation
at low b value regime, which can be described by a second exponen-
tial component in the intravoxel incoherent motion (IVIM) theory
proposed by Le Bihan [15], which enables calculations of true diffu-
sion coefﬁcient (D), perfusion fraction (PF or f), and pseudodiffusion
coefﬁcient (D*). Recently, the IVIM model has been applied for
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ssessment of diffuse liver disease [16–20] and for characterization
f focal liver lesions [21–24]. Two recent studies have investigated
he role of IVIM in treated tumors [25,26]. Wagner et al. [25] (in
8 patients with 28 HCCs and 12 metastases) demonstrated sig-
iﬁcantly higher D/lower PF values in necrotic vs. viable tumor
omponents, while ADC and D* showed no difference. Chiaradia
t al. [26] (in 15 patients with 35 colorectal cancer metastases)
howed that both D (r = 0.36, p = 0.035) and ADC (r = 0.4, p = 0.02)
orrelated signiﬁcantly with the degree of tumor necrosis.
The objectives of our study were to: (a) correlate IVIM diffusion
arameters of liver parenchyma and HCC with degree of liver and
umor enhancement and necrosis; (b) assess the diagnostic perfor-
ance of IVIM parameters and of enhancement ratios for prediction
f complete tumor necrosis in HCC post locoregional therapy.
. Materials and methods
.1. Study population
Approval for this single center retrospective HIPAA compliant
tudy was obtained from our Institutional Review Board, with
 waiver for informed consent. IVIM DW-MRI was  acquired in
ll patients undergoing routine liver MRI  at 3.0 T from July 2011
hrough November 2011.
We applied the following inclusion criteria:
) Adult patients (age >18 years) with chronic liver disease.
) With untreated or treated HCC (post locoregional therapy) with
a size above 1 cm.
) Imaged on the same 3.0 T system.
) Underwent IVIM DW-MRI and contrast-enhanced imaging.
Exclusion criteria:
) Patients with only small HCC (size <10 mm)  (n = 8).
) Missing IVIM DW-MRI or contrast-enhanced imaging (n = 4).
) Patients with lesions other than HCC (n = 12).
Seventy patients were identiﬁed, and 24 were excluded. The
nal patient population included 46 patients (23 men  and 23
omen, mean age 61 years, range 23–81 years). Forty-three
atients had liver cirrhosis. The etiology of liver disease included
hronic hepatitis C (n = 34), chronic hepatitis B (n = 4), NASH (n = 2),
ryptogenic (n = 3), alcohol abuse (n = 2), autoimmune hepatitis
n = 1). There were 19 patients with HCC naïve to therapy, and
7 patients who underwent locoregional therapy for HCC, which
ncluded transarterial chemoembolization (TACE, n = 17), a combi-
ation of TACE and RFA (n = 8), RFA (n = 1) or microwave ablation
n = 1), with a mean/median delay of 148/100 days (range, 27–627
ays) before the MRI  exam.
. MRI
MRI  was performed using a 3.0 T clinical system (Discovery
R750; GE Healthcare, MW,  USA) and a 32-channel torso coil. The
rotocol included axial fat suppressed free breathing single shot
choplanar imaging DW-MRI with diffusion gradients obtained in
hree orthogonal directions [TR/TE 3000/min. (55–58), ﬂip angle
0◦, 80 × 128, FOV 350–400, slice/gap 8/1.6 mm,  parallel imag-
ng ASSET factor 2, 16 b values: 0, 15, 30, 45, 60, 75, 90, 105,
20, 135, 150, 175, 200, 400, 600, 800 s/mm2, 1 average for b
, 15, 30 and 2 averages for the remaining b values, acquisition
ime 3:45 min], axial fat suppressed breath-hold FSE T2-WI (TR/TE
800/100, 256 × 256, slice/gap 7.5/1 mm,  FOV 350–400), axial and
oronal SS fast spin echo T2WI (TR/TE 600/80 for coronal-240 forRadiology Open 3 (2016) 1–7
axial, 256 × 320, slice/gap 5/1 mm,  FOV 350–400), breath-hold 2D
axial in- and opposed-phase T1WI (TR/TE 3.8/2.2–1.1, ﬂip angle 12◦,
320 × 224, slice/gap 4/1 mm),  and axial 3D GRE T1WI (LAVA, TR/TE
4.1/1.86, ﬂip angle 10◦, 192 × 320, slice thickness 4.4 mm,  FOV
350–400 mm)  before and after contrast injection [0.01 mmol/kg of
gadopentetate dimeglumine (Magnevist, Bayer Healthcare Phar-
maceuticals, n = 20) or gadobutrol (Gadavist/Gadovist, n = 6) and
10 mL  ﬁxed dose of gadoxetic acid (Eovist/Primovist, n = 20)]. Post-
contrast images were obtained at the early and late arterial phases
(timed using bolus tracking), portal venous phase (60 s) and late
venous phase (180 s). Hepatobiliary phase images were obtained
at 10 and 20 min. in patients who received gadoxetic acid.
3.1. Image analysis
3.1.1. Identiﬁcation of index lesions
Two experienced observers (observer 1 and observer 2; with 13
and 9 year’s experience, respectively) reviewed the images in con-
sensus using a clinical PACS (Centricity v.3.0 GE, MW,  USA). The
goal of this review was  to identify HCC lesions on conventional
sequences. An HCC was diagnosed if the lesion fulﬁlled any two
of the four following criteria: (1) arterial hyperenhancement, (2)
portal venous or late venous washout, (3) capsule/pseudocapsule,
and (4) mild to moderate hyperintensity on T2WI or high b value
DW-MRI (compared with surrounding liver parenchyma) [27].
Treated HCCs were diagnosed in the presence of necrotic or par-
tially necrotic lesions post locoregional therapy. Up to 5 lesions per
patient were evaluated.
3.1.2. Assessment of tumor necrosis
The two observers measured in consensus the percentage of
tumor necrosis using image subtraction with 10% increments
as described previously [28]. This method has been validated
against histopathology, with substantial interobserver agreement
for assessment of percentage tumor necrosis (k 0.601–0.708) [28].
3.1.3. Quantitative evaluation
Observer 1 measured signal intensity (SI, au) by placing regions
of interest (ROIs) within the index lesions and liver parenchyma
on DW and T1WI pre- and post-contrast-enhanced images using a
DICOM viewer (Osirix v.4.1.2, Pixmeo, Geneva, Switzerland). ROIs
encompassed the whole lesion and were copied from contrast-
enhanced images and pasted to DW images, and adjusted as
needed. In large lesions (with a diameter larger than 30 mm), 3
ROIs were placed on contiguous slices and SI was  averaged. Three
ROIs (measuring at least 20 mm2) were also placed within the right
hepatic lobe (on 3 adjacent slices centered around the portal vein
bifurcation) to measure liver SI. The left lobe of liver was not used
due to cardiac motion artifacts, which can potentially alter diffu-
sion measurement. In partially necrotic lesions, SI was measured
on DW images, by placing ROIs in the necrotic and viable areas.
The mean SI of DW images was ﬁtted to the IVIM equation
[15,20] which models the SI decay with increasing b values as a
fast pseudo-diffusion of constant D* (pseudodiffusion coefﬁcient)
for the extravascular water fraction PF (perfusion fraction), and a
slow molecular diffusion constant D (true diffusion coefﬁcient) for
the non-ﬂowing spins:
SIb = SI0[PFe−bD∗ + (1 − PF)e−bD]
SIb is the signal intensity (SI) at as an arbitrary b value. SI0 is the
SI in the absence of diffusion weighting (b = 0 s/mm2). We  used
a Bayesian ﬁtting method to estimate the IVIM parameters [20].
A Bayesian ﬁtting method was implemented with in-house soft-
ware programmed in Matlab (Matlab 2011a, Mathworks, MA,  USA).
ADC was calculated with mono-exponential ﬁt by using the follow-
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Fig. 1. 59 year-old male patient with partially necrotic HCC post TACE. (a) Axial contrast-enhanced T1 weighted image obtained at portal venous phase, (b) axial fat suppressed
SS  EPI DW image at b800. Both demonstrate a partially necrotic HCC with solid enhancing component with restricted diffusion (arrow) and nonenhancing necrotic component
h I placement in solid and necrotic components. (d) Fitting diffusion curve in whole HCC
l /background liver: D 1.21/1.57/0.77 × 10−3 mm2/s, D* 17.53/9.44/8.03 × 10−3 mm2/s, PF
1 (during portal venous phase) 113.0%/−16.4%/47.8%.
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Table 1
Diffusion parameters and enhancement ratios measured in all HCC lesions (includ-
ing partially/completely necrotic and solid HCCs) and solid HCCs vs. background
liver parenchyma.
All HCCs (n = 79) Liver parenchyma (n = 46) p*
D 1.128 ± 0.244 1.014 ± 0.177 <0.0001
D*  41.942 ± 47.616 45.959 ± 39.932 0.64
PF  21.205 ± 10.718 14.353 ± 6.004 <0.0001
ADC  1.377 ± 0.280 1.152 ± 0.155 <0.0001
ER  AP 47.50 ± 41.33 32.97 ± 18.18 0.012
ER  PVP 47.56 ± 39.44 58.89 ± 19.21 0.03
ER  LVP 41.06 ± 33.45 52.36 ± 16.29 0.007
Solid HCCs (n = 39) Liver parenchyma (n = 39) p*
D 1.047 ± 0.215 0.981 ± 0.161 0.14
D*  52.532 ± 58.900 36.615 ± 30.810 <0.0001
PF  24.554 ± 11.356 17.297 ± 6.711 <0.0001
ADC  1.299 ± 0.240 1.141 ± 0.164 <0.0001
ER  AP 69.75 ± 39.97 31.81 ± 16.47 <0.0001
ER  PVP 69.09 ± 34.25 59.64 ± 16.97 0.04
ER  LVP 56.13 ± 28.72 53.43 ± 13.88 0.74
D, true diffusion coefﬁcient (×10−3 mm2/s), D*, pseudodiffusion coefﬁcient
(×10−3 mm2/s), PF, perfusion fraction (%), ADC, apparent diffusion coefﬁcient, ER,ypointense on DW-MRI (short arrows). (c) Magniﬁed b800 DW image shows RO
esion. The following parameters were obtained in solid/necrotic HCC components
5.81%/23.33%/21.58%, ADC 1.47/1.97/1.09 × 10−3 mm2/s, and enhancement ratios 
ng equation: SIb1/SIb2 = e−(b1 − b2)ADC. We  calculated the ADC value
sing all 16 b values. D, D*, PF and ADC were obtained in back-
round liver, whole HCC lesions, and in viable/necrotic components
f partially necrotic lesions (Fig. 1).
Additionally, enhancement ratios (ER) were calculated in HCC
whole lesions) and liver parenchyma on dynamic post-contrast
hases (2nd arterial, portal venous and late venous phases), using
he following formula: ER = (SIpost – SIpre)/SIpre; where SIpost is
ean SI measured on contrast-enhanced images, and SIpre is mean
I measured on unenhanced images.
.2. Statistical analysis
Diffusion parameters were compared between tumor tissue and
ackground liver using a non-parametric Wilcoxon signed-rank
est. A Spearman correlation was performed between diffusion
arameters and enhancement ratios in the liver and HCC tumors,
s well as between each of diffusion parameters and enhancement
atios with% tumor necrosis. A non-parametric Mann–Whitney U
est was used to compare diffusion parameters between viable
nd necrotic tumor compartments. ROC analysis was  performed to
ssess the diagnostic performance of diffusion metrics vs. enhance-
ent ratios for prediction of complete tumor necrosis (100%). Areas
nder the curve were compared using a DeLong test. All statistical
nalysis was performed using Matlab R2013b statistical toolbox.
enhancement ratio (%), AP, arterial phase, PVP, portal venous phase, LVP, late venous
phase.
Signiﬁcant p-values are bolded.
* Wilcoxon signed-rank test.
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Table 2
Spearman correlations between IVIM DW-MRI parameters and enhancement ratios
measured with contrast-enhanced T1-weighted imaging in all HCCs. There were
signiﬁcant correlations between D/PF and enhancement ratios in HCC.
Liver parenchyma ER AP (%) ER PVP (%) ER LVP (%)
D r 0.206 0.107 0.232
p  0.067 0.34 0.039
D* r  0.146 0.310 0.314
p  0.19 0.005 0.004
PF r  −0.07 −0.009 −0.018
p  0.53 0.93 0.87
ADC r 0.172 0.001 0.167
p  0.12 0.98 0.13
HCC  ER AP ER PVP ER LVP
D r  −0.288 −0.357 −0.344
p  0.009 0.001 0.001
D* r  0.078 0.044 −0.005
p  0.493 0.695 0.962
PF r  0.364 0.309 0.281
p  <0.001 0.005 0.011
ADC r  −0.084 −0.167 −0.172
p  0.45 0.139 0.128
D, true diffusion coefﬁcient (×10−3 mm2/s), D*, pseudodiffusion coefﬁcient
(×10−3 mm2/s), PF, perfusion fraction (%), ADC, apparent diffusion coefﬁcient, ER,
enhancement ratio (%), AP, arterial phase, PVP, portal venous phase, LVP, late venous
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Table 3
Diffusion parameters and enhancement ratios in necrotic tumor components
(including completely necrotic lesions and necrotic components of partially necrotic
lesions) and viable tumor components (including viable components of partially
necrotic lesions and solid lesions). There were signiﬁcant differences in D/ADC and
enhancement ratios between necrotic and viable components, but not in PF/D*.
Viable tumor (n = 58) Necrotic tumor (n = 40) p*
D 1.052 ± 0.231 1.299 ± 0.250 <0.0001
D*  42.720 ± 51.911 27.114 ± 24.655 0.179
PF  22.373 ± 11.497 18.153 ± 8.342 0.155
ADC  1.313 ± 0.280 1.570 ± 0.334 <0.001
ER  AP 67.15 ± 41.8 10.46 ± 14.53 <0.0001
ER  PVP 76.3 ± 65.6 9.31 ± 18.0 <0.0001
ER  LVP 58.3 ± 32.1 11.5 ± 17.3 <0.0001
D, true diffusion coefﬁcient (×10−3 mm2/s), D*, pseudodiffusion coefﬁcient
(×10−3 mm2/s), PF, perfusion fraction (%), ADC, apparent diffusion coefﬁcient, ER,
enhancement ratio (%), AP, arterial phase, PVP, portal venous phase, LVP, late venous
phase.
Signiﬁcant p-values are bolded.
* Mann–Whitney U test.
Table 4
ROC analysis for prediction of complete tumor necrosis using diffusion parameters
and enhancement ratios. 95% conﬁdence intervals for sensitivity and speciﬁcity are
given in parentheses.
Measure Threshold AUC Sensitivity (%) Speciﬁcity (%)
D 1.15 0.811 85.7 (64.2–100) 67.2 (55.2–78.9)
D* 22.45 0.529 44.0 (31.3–58.4) 68.9 (47.9–84.1)
PF 17.99 0.625 53.4 (40.9–67.2) 66.6 (42.6–84.2)
ADC 1.37 0.740 71.4 (47.4–88.0) 65.5 (51.7–77.0)
ER AP 22.5 0.953 86.2 (75.4–94.2) 95.2 (76.0–100)
ER PVP 25.3 0.977 94.8 (87.2–100) 90.4 (69.2–100)
ER  LVP 19.8 0.972 93.1 (83.5–98.2) 95.2 (72.6–100)
D, true diffusion coefﬁcient (×10−3 mm2/s), D*, pseudodiffusion coefﬁcient
(×10−3 mm2/s), PF, perfusion fraction (%), ADC, apparent diffusion coefﬁcient, ER,hase.
igniﬁcant p-values are bolded.
. Results
Seventy-nine HCCs (mean size 2.5 ± 2.0 cm,  range 1.0–14.0 cm)
ere assessed in 46 patients. These included 41 untreated HCCs
n 19 patients, and 38 treated HCCs in 27 patients. There were 29
atients with a single HCC evaluated, 8 with 2HCCs, and 9 with more
han 2HCCs. Three patients had both untreated and treated lesions.
ean percentage necrosis on subtraction was 37.0% ± 44.5% (range,
–100%). 19 lesions were partially necrotic (>5% necrosis), 21 were
ompletely necrotic (100% necrosis), and 39 were solid (0% necro-
is).
HCCs were diagnosed using imaging criteria in 31 patients,
r histopathologically in 15 patients (with 19HCCs), by means of
esection (n = 7), transplantation (n = 6) or biopsy (n = 2). The mean
elay from MRI  to pathologic conﬁrmation was 135 days (range,
2–302 days). The delay was less than 90 days in 7 patients,
recluding the use of pathologic necrosis as en endpoint. The
ollowing grade distribution was observed in pathologically con-
rmed lesions: well differentiated (7 lesions), well to moderately
ifferentiated (1 lesion), moderately differentiated (8 lesions),
oorly differentiated (2 lesions) and completely necrotic (1 lesion).
D, PF and ADC were all signiﬁcantly higher when comparing
ll tumors (including partially/completely necrotic and solid HCCs)
ompared to background liver (Table 1), while there was no differ-
nce in D* values. When comparing solid HCCs vs. liver, D*/PF/ADC
ere all signiﬁcantly higher than in liver parenchyma, while no
igniﬁcant difference was observed for D (Table 1). Enhancement
atios were signiﬁcantly higher in all HCCs at the arterial phase,
nd signiﬁcantly lower at portal venous and late venous phases
ompared to liver parenchyma; while solid HCCs had signiﬁcantly
igher enhancement ratios at the arterial and portal venous phase
ompared to liver parenchyma.
There were weak correlations between D/D* and liver enhance-
ent ratios at the portal venous and late venous phases (Table 2).
n HCC, there were weak but signiﬁcant negative/positive corre-
ations only between D/PF and enhancement ratios. ADC did not
orrelate with any enhancement ratio. D/ADC were signiﬁcantly
igher in necrotic tissue compared to viable tissue; while enhance-
ent ratios were signiﬁcantly lower (Table 3, Figs. 1 and 2). Thereenhancement ratio (%), AP, arterial phase, PVP, portal venous phase, LVP, late venous
phase.
were no signiﬁcant differences in PF/D* between necrotic and viable
tissue. There were signiﬁcant correlations between D/PF/ADC and
percentage tumor necrosis (Fig. 3) as follows: D (r = 0.452, p < 0.001),
D* (r = −0.151, p = 0.18), PF (r = −0,298, p = 0.007), ADC (r = 0.346,
p = 0.001). The correlations between enhancement ratios and%
necrosis were stronger [ER AP (r = −0,683, p < 0.0001); ER PVP
(r = −0,689, p < 0.0001), ER LVP (r = −0,625, p < 0.0001)].
Among diffusion parameters, D had the highest AUC (0.811)
for predicting complete tumor necrosis, which was  signiﬁcantly
higher than the AUCs achieved by PF and D* (p = 0.003 and 0.026,
respectively) (Table 4, Fig. 4). Enhancement ratios signiﬁcantly out-
performed diffusion parameters for prediction of complete tumor
necrosis (AUC > 0.95, p < 0.002). The combination of D and enhance-
ment ratio at the portal venous phase minimally improved the AUC
to 0.982 without reaching signiﬁcance, with sensitivity of 0.95 and
speciﬁcity of 0.95.
5. Discussion
In this study, we have demonstrated that both perfusion and
diffusion coefﬁcients are higher in HCC vs. liver parenchyma when
comparing a mix  of treated and untreated HCCs to background liver
parenchyma. This difference did not hold true for true molecular
diffusion (D) when comparing only solid HCCs to liver parenchyma.
We found weak correlations between diffusion parameters and
enhancement ratios. In addition, necrotic changes post locoregional
therapy were concomitant with increased D and ADC (apparent
diffusion coefﬁcient), without signiﬁcant changes in PF (perfu-
sion fraction). Therefore, we believe that ADC increase in tumor
necrosis may  be mostly attributed to an increase in true molec-
S. Kakite et al. / European Journal of Radiology Open 3 (2016) 1–7 5
F  durin
D mm2/
r
u
a
n
>
t
a
F
(
Dig. 2. Box-plot distribution of IVIM parameters and enhancement ratios (obtained
:  true diffusion coefﬁcient (×10−3 mm2/s), D*: pseudodiffusion coefﬁcient (×10−3
atio  (%), AP: arterial phase, PVP: portal venous phase.
lar diffusion without a signiﬁcant decrease in PF. Finally, D had
 reasonable accuracy (AUC 0.811) for predicting complete tumor
ecrosis, although lower than that of enhancement ratios (AUC
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The diagnosis of complete HCC tumor necrosis after locoregional
herapy or lack thereof is essential, as it determines the need for
dditional TACE therapy or alternate treatments. Pre-clinical and
ig. 3. Correlation plots between each of IVIM DW-MRI parameters and enhancement ra
x-axis) assessed on image subtraction.
: true diffusion coefﬁcient (×10−3 mm2/s), PF: perfusion fraction (%), ADC: apparent diffg arterial and portal venous phases) in necrotic and solid HCC components.
s), PF: perfusion fraction (%), ADC: apparent diffusion coefﬁcient, ER: enhancement
clinical studies have shown that necrotic tumors yield higher ADC
values compared with viable tumor components [4,5], with an
observed increase in ADC after locoregional or systemic therapy
[6,10,11,13]. Few studies have reported a correlation between ADC
and necrosis post therapy [14]. For example, Mannelli et al. [14]
reported a signiﬁcant correlation between ADC and tumor necrosis
post TACE assessed on liver explant (r = 0.64, p < 0.001). For pre-
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e found a weak correlation between % necrosis and ADC (r = 0.346,
 = 0.001), inferior to that reported by Mannelli et al. [14]. This could
e explained by differences in the delay between treatment and
maging (38 days in the study by Mannelli vs. 148 days in the current
tudy).
Although ADC is the most frequently used diffusion parameter
utside the brain, it is a composite parameter with both diffusion
nd perfusion contributions. Biologically, it is more appropriate to
eparate the two components by using a biexponential IVIM model
escribed in the pioneering work by Le Bihan [15]. The IVIM model
as been applied for assessment of diffuse liver disease [16–20],
nd for characterization of focal liver lesions [21,22,24]. Investiga-
ors have used between 8 and 16 b values in the liver, with the
ighest b value ranging between 500 and 1000 [16–20,24–26,29].
n our study, we report D values similar to previously reported
alues in liver parenchyma [16–20,24,26,29] and HCC/liver metas-
ases (range from literature 0.98 to 1.19 × 10−3 mm2/s for liver
irrhosis, and 0.97–1.70 × 10−3 mm2/s for HCC/liver metastases)
19,24–26,29], the highest D values (1.70 × 10−3 mm2/s) were
eported for necrotic lesions [25]. These values are to be com-
ared to mean D (×10−3 mm2/s) of 1.01 for liver and 1.052/1.299
or viable/necrotic tumors in our study. On the other hand, our
eported ADC and PF values in liver parenchyma are on the
ower end of the spectrum compared to other studies (range of
eported ADC 1.15–1.41 × 10−3 mm2/s, for PF 10.7–30.8% in cirrho-
is) [16–20,24,26,29]. This may  be due to differences in low b values
istribution. D* values are highly variable, with low reproducibil-
ty of this parameter recently reported [20,29]. There is a need to
tandardize the acquisition parameters in IVIM in order to apply
his technique in the clinic.
Two recent studies have assessed the role of IVIM parameters
n treated liver tumors [25,26]. Wagner et al. [25] (using 11 b val-
es in 48 patients with 28HCCs and 12 metastases) demonstrated
igniﬁcantly higher D/lower PF values in necrotic vs. viable tumor
omponents, while ADC and D* showed no difference. Chiaradia
t al. [26] (using 10 b values in 15 patients with 35 resected col-
rectal cancer metastases) showed that both D (r = 0.36, p = 0.035)enous phase, and combination of D + ER for prediction of complete tumor necrosis
ncement ratio (%), PVP: portal venous phase.
and ADC (r = 0.4, p = 0.02) correlated signiﬁcantly with the degree
of tumor necrosis, while PF did not. We consider our results to be
inline with these two  studies, except for the fact that PF did not vary
between necrotic and solid tumors. These studies and ours seem to
indicate that increased ADC in necrosis is mostly due to an increase
in D, and is less affected by PF.
Variable correlations have been observed between IVIM param-
eters and tissue enhancement or perfusion. Signiﬁcant correlations
(with r ranging from 0.42 to 0.70) have been reported in renal
tumors [30] and HCC [24], while no correlation was observed
when comparing with DCE-MRI in liver parenchyma [17]. In our
study, there were modest positive correlations between PF and
enhancement ratios in HCC. Interestingly, D had a weak but sig-
niﬁcant negative correlation with tumor enhancement, which
should be veriﬁed prospectively. These modest correlations are
not surprising, because the IVIM model provides pure intravascular
information and DCE-MRI provides perfusion information includ-
ing extravasation with a larger temporal scale. Henkelman et al.
[31] suggested that IVIM does not measure tissue perfusion as does
DCE-MRI, as it is more sensitive to blood volume transit through a
voxel.
There are several limitations in this study. First, although the
data was  prospectively acquired, we did not include serial imag-
ing pre- and post therapy, and we had variable delays between
treatment and imaging. Second, we did not assess necrosis on
histopathology, since only a small proportion of patients did
undergo tissue sampling within 90 days after MRI  (n = 7). Of
note, image subtraction has been previously validated against
histopathology [28].
In conclusion, we  observed higher IVIM diffusion parameters in
treated and untreated HCCs compared to liver parenchyma; weak
correlations between IVIM parameters and tumor enhancement;
and signiﬁcant correlation between D/PF and degree of tumor
necrosis. D has an acceptable AUC for prediction of complete tumor
necrosis, better than that of ADC and PF, but lower than that of
enhancement ratios. IVIM DW-MRI may  have additional adjunct
value for assessing HCC response in prospective trials and/or in
patients who could not receive gadolinium contrast.
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